Product Description
ETX-155 is an investigational novel, oral, next generation, neurosteroid GABAA PAM that demonstrates dual synaptic and extrasynaptic receptor activity with an approximate 24-hour half-life and no clinically meaningful food effect. Preclinical and Phase 1 clinical data demonstrate the potential for ETX-155 to be a best-in-class treatment for multiple neuronal excitability disorders. (Sourced from: https://eliemtx.com/pipeline/)
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eliem Therapeutics
Company Location:
Company Founding Year: 2018
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Epilepsy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/09/2023 |
News Article |
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition |
|
10/05/2022 |
News Article |
Eliem Therapeutics Provides Update on Pipeline Progress |
|
08/02/2022 |
News Article |
Eliem Therapeutics Provides ETX-810 Program Update |
|
07/18/2022 |
News Article |
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder |